ATE372113T1 - Aminoalkoxyindol-derivate als 5-ht6- rezeptorliganden zur bekämpfung von zns- krankheiten - Google Patents
Aminoalkoxyindol-derivate als 5-ht6- rezeptorliganden zur bekämpfung von zns- krankheitenInfo
- Publication number
- ATE372113T1 ATE372113T1 AT03782240T AT03782240T ATE372113T1 AT E372113 T1 ATE372113 T1 AT E372113T1 AT 03782240 T AT03782240 T AT 03782240T AT 03782240 T AT03782240 T AT 03782240T AT E372113 T1 ATE372113 T1 AT E372113T1
- Authority
- AT
- Austria
- Prior art keywords
- aminoalkoxyindole
- fight
- derivatives
- receptor ligands
- cns diseases
- Prior art date
Links
- 108091005435 5-HT6 receptors Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43050602P | 2002-12-03 | 2002-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE372113T1 true ATE372113T1 (de) | 2007-09-15 |
Family
ID=32469485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03782240T ATE372113T1 (de) | 2002-12-03 | 2003-11-27 | Aminoalkoxyindol-derivate als 5-ht6- rezeptorliganden zur bekämpfung von zns- krankheiten |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US7084169B2 (de) |
| EP (1) | EP1569638B1 (de) |
| JP (1) | JP4339795B2 (de) |
| KR (1) | KR100755580B1 (de) |
| CN (1) | CN1713908B (de) |
| AR (1) | AR042155A1 (de) |
| AT (1) | ATE372113T1 (de) |
| AU (1) | AU2003289903B2 (de) |
| BR (1) | BR0316962A (de) |
| CA (1) | CA2508315A1 (de) |
| DE (1) | DE60316180T2 (de) |
| ES (1) | ES2291722T3 (de) |
| HR (1) | HRP20050457A2 (de) |
| MX (1) | MXPA05005790A (de) |
| MY (1) | MY138466A (de) |
| NO (1) | NO20052730L (de) |
| NZ (1) | NZ539950A (de) |
| PA (1) | PA8589801A1 (de) |
| PE (1) | PE20040763A1 (de) |
| PL (1) | PL377464A1 (de) |
| RU (1) | RU2350602C2 (de) |
| TW (1) | TWI284124B (de) |
| WO (1) | WO2004050085A1 (de) |
| ZA (1) | ZA200504412B (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5417142A (en) * | 1992-12-18 | 1995-05-23 | Caterpillar Inc. | Hydraulic amplifier |
| RU2309154C9 (ru) | 2002-03-27 | 2016-09-27 | Глэксо Груп Лимитед | 3-фенилсульфонил-8-пиперазин-1-ил-хинолины, обладающие аффинностью к 5-нт6 рецептору, способы их получения (варианты) |
| DE602004000260T2 (de) | 2003-07-22 | 2006-08-24 | Arena Pharmaceuticals, Inc., San Diego | Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen |
| GB0500604D0 (en) * | 2005-01-13 | 2005-02-16 | Astrazeneca Ab | Novel process |
| US20090221644A1 (en) * | 2005-06-30 | 2009-09-03 | Stuart Edward Bradley | Gpcr Agonists |
| RU2429231C2 (ru) * | 2005-08-15 | 2011-09-20 | Вайет | Производные замещенного-3-сульфонилиндазола в качестве лигандов 5-гидрокситриптамина-6 |
| US7645752B2 (en) * | 2006-01-13 | 2010-01-12 | Wyeth Llc | Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors |
| MX2008013053A (es) | 2006-04-12 | 2008-10-17 | Wyeth Corp | Derivados de dihidri[1,4]oxazino[2,3,4-hi]indazol-sustituidos como ligandos de 5-hidroxitriptamina-6. |
| US20100041672A1 (en) * | 2007-03-21 | 2010-02-18 | Glaxo Group Limited | Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome |
| EP2508177A1 (de) | 2007-12-12 | 2012-10-10 | Glaxo Group Limited | Kombinationen mit 3-phenylsulfonyl-8-piperazinyl-1yl-chinolin |
| US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
| CN102558020B (zh) * | 2011-12-12 | 2013-09-18 | 温州大学 | 一种3-芳巯基吲哚类化合物的合成方法 |
| CN103288707B (zh) * | 2013-05-28 | 2015-12-23 | 浙江大学 | 一种3-苯巯基吲哚衍生物的制备方法 |
| EP3166924B1 (de) | 2014-07-08 | 2019-02-20 | Sunshine Lake Pharma Co., Ltd. | Aromatische heterocyclische derivate und pharmazeutische anwendungen davon |
| US10022355B2 (en) | 2015-06-12 | 2018-07-17 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder |
| BR112018000728A2 (pt) | 2015-07-15 | 2018-09-04 | Axovant Sciences Gmbh | resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1139760A (en) | 1979-03-07 | 1983-01-18 | Makiko Sakai | 1,4-dioxaspiro¬4,5| decene compounds |
| FR2589863B1 (fr) | 1985-11-12 | 1988-07-29 | Sanofi Sa | Derives d'hydroxy-4 indole, leur procede de preparation et leur utilisation |
| US5254595A (en) | 1988-12-23 | 1993-10-19 | Elf Sanofi | Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them |
| US4939138A (en) * | 1988-12-29 | 1990-07-03 | Sterling Drug Inc. | 2- and 3-aminomethyl-6-arylcarbonyl-2,3-dihydropyrrolo(1,2,3-DE)-1,4-benzoxazines |
| GB9125900D0 (en) * | 1991-12-05 | 1992-02-05 | Wyeth John & Brother Ltd | Piperazine derivatives |
| FR2740686B1 (fr) | 1995-11-03 | 1998-01-16 | Sanofi Sa | Formulation pharmaceutique lyophilisee stable |
| CA2264080A1 (en) * | 1996-08-27 | 1998-03-05 | Richard Eric Mewshaw | 4-aminoethoxy indoles as dopamin d2 agonists and as 5ht1a ligands |
| GB9902452D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| FR2791344B1 (fr) | 1999-03-25 | 2002-02-15 | Adir | Nouveaux derives dimeriques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR2793793B1 (fr) | 1999-05-19 | 2004-02-27 | Adir | Nouveaux derives dimeriques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| TWI222450B (en) * | 1999-07-28 | 2004-10-21 | Upjohn Co | Oxazinocarbazoles for the treatment of CNS diseases |
| TW593278B (en) * | 2001-01-23 | 2004-06-21 | Wyeth Corp | 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| CN1293073C (zh) * | 2001-04-20 | 2007-01-03 | 惠氏公司 | 作为5-羟色胺-6配体的杂环基烷氧基-、-烷硫基-和-烷基氨基吲哚衍生物 |
-
2003
- 2003-11-27 WO PCT/EP2003/013372 patent/WO2004050085A1/en not_active Ceased
- 2003-11-27 PL PL377464A patent/PL377464A1/pl not_active Application Discontinuation
- 2003-11-27 RU RU2005121125/04A patent/RU2350602C2/ru not_active IP Right Cessation
- 2003-11-27 AU AU2003289903A patent/AU2003289903B2/en not_active Ceased
- 2003-11-27 HR HR20050457A patent/HRP20050457A2/hr not_active Application Discontinuation
- 2003-11-27 ES ES03782240T patent/ES2291722T3/es not_active Expired - Lifetime
- 2003-11-27 EP EP03782240A patent/EP1569638B1/de not_active Expired - Lifetime
- 2003-11-27 JP JP2004556206A patent/JP4339795B2/ja not_active Expired - Fee Related
- 2003-11-27 CA CA002508315A patent/CA2508315A1/en not_active Abandoned
- 2003-11-27 AT AT03782240T patent/ATE372113T1/de not_active IP Right Cessation
- 2003-11-27 KR KR1020057010127A patent/KR100755580B1/ko not_active Expired - Fee Related
- 2003-11-27 BR BR0316962-6A patent/BR0316962A/pt not_active IP Right Cessation
- 2003-11-27 CN CN2003801040190A patent/CN1713908B/zh not_active Expired - Fee Related
- 2003-11-27 NZ NZ539950A patent/NZ539950A/en unknown
- 2003-11-27 TW TW092133339A patent/TWI284124B/zh not_active IP Right Cessation
- 2003-11-27 DE DE60316180T patent/DE60316180T2/de not_active Expired - Lifetime
- 2003-11-27 MX MXPA05005790A patent/MXPA05005790A/es active IP Right Grant
- 2003-11-28 PE PE2003001211A patent/PE20040763A1/es not_active Application Discontinuation
- 2003-11-28 PA PA20038589801A patent/PA8589801A1/es unknown
- 2003-12-01 AR ARP030104414A patent/AR042155A1/es unknown
- 2003-12-01 US US10/724,683 patent/US7084169B2/en not_active Expired - Fee Related
- 2003-12-02 MY MYPI20034589A patent/MY138466A/en unknown
-
2005
- 2005-05-30 ZA ZA200504412A patent/ZA200504412B/en unknown
- 2005-06-07 NO NO20052730A patent/NO20052730L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP4339795B2 (ja) | 2009-10-07 |
| JP2006509777A (ja) | 2006-03-23 |
| US20040132799A1 (en) | 2004-07-08 |
| MXPA05005790A (es) | 2005-10-18 |
| KR20050084155A (ko) | 2005-08-26 |
| CN1713908B (zh) | 2010-05-12 |
| EP1569638B1 (de) | 2007-09-05 |
| PA8589801A1 (es) | 2004-11-26 |
| AU2003289903A1 (en) | 2004-06-23 |
| PL377464A1 (pl) | 2006-02-06 |
| TWI284124B (en) | 2007-07-21 |
| ZA200504412B (en) | 2006-04-26 |
| KR100755580B1 (ko) | 2007-09-06 |
| NZ539950A (en) | 2007-05-31 |
| AU2003289903B2 (en) | 2008-06-26 |
| CA2508315A1 (en) | 2004-06-17 |
| NO20052730D0 (no) | 2005-06-07 |
| DE60316180D1 (de) | 2007-10-18 |
| BR0316962A (pt) | 2005-10-25 |
| MY138466A (en) | 2009-06-30 |
| RU2005121125A (ru) | 2006-02-20 |
| US7084169B2 (en) | 2006-08-01 |
| CN1713908A (zh) | 2005-12-28 |
| PE20040763A1 (es) | 2004-11-20 |
| NO20052730L (no) | 2005-08-23 |
| EP1569638A1 (de) | 2005-09-07 |
| ES2291722T3 (es) | 2008-03-01 |
| AR042155A1 (es) | 2005-06-08 |
| WO2004050085A1 (en) | 2004-06-17 |
| RU2350602C2 (ru) | 2009-03-27 |
| HRP20050457A2 (en) | 2005-10-31 |
| DE60316180T2 (de) | 2008-05-29 |
| TW200413312A (en) | 2004-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE372113T1 (de) | Aminoalkoxyindol-derivate als 5-ht6- rezeptorliganden zur bekämpfung von zns- krankheiten | |
| CY2016035I2 (el) | Θεραπευτικη χρηση αντισωματων anti-cs1 | |
| DK1656347T3 (da) | Substituerede indolderivater til farmaceutisk sammensætning til behandling af luftvejssygdomme | |
| NO330884B1 (no) | Pustende vanntett sale for sko | |
| NO20052914D0 (no) | Terapeutiske forbindelser | |
| DE60328671D1 (de) | Neue aminobenzamidderivate | |
| DK1587386T3 (da) | Vandtæt fodtøj | |
| DE60336811D1 (de) | Neue benzimidazolderivate | |
| DE60316012D1 (de) | Purinderivate und ihre verwendung als liganden des cannabinoid rezeptors | |
| CY1107400T1 (el) | Συνταγοποιηση κοκκου μοντελουκαστης | |
| IS7728A (is) | Aðferð til að framleiða kalsíumsalt rósuvastatíns | |
| ATE497953T1 (de) | Thiazolderivate als modulatoren des cannabinoidrezeptors | |
| ATE396191T1 (de) | Azaindolylalkylaminderivate als 5- hydroxytryptamin-6-liganden | |
| DE602004022805D1 (de) | Quinuclidin-derivate bindend an muscarin-m3-rezeptoren | |
| ATE421506T1 (de) | Neue benzimidazolderivate | |
| DK1691607T3 (da) | Anvendelse af N-arylhydrazinderivater til bekæmpelse af skadedyr | |
| DE60319997D1 (de) | Topische emulsionsgel-zubereitung enthaltend diclofenac-natrium | |
| DK1622612T3 (da) | Farmaceutisk formulering af natriumsaltet af telmitarsan | |
| DE60322030D1 (de) | Lichtempfindliches element zur benutzung als flexodruckplatte | |
| DE60311822D1 (de) | Neue piperazinyl-pyrazinon-derivate zur behandlung von 5-ht2a rezeptor-bedingten erkrankungen | |
| ATE389652T1 (de) | Benzothiazol-derivate als liganden des adenosinrezeptors | |
| ATE499348T1 (de) | Stabiler polymorph von bifeprunoxmesilat | |
| EP1684794A4 (de) | Verändern tierischer abfallzusammensetzung | |
| EP1554929A4 (de) | Künstlicher sauger für versuchstiere | |
| GB0312539D0 (en) | Improvements relating to gutters |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1569638 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |